VEON Ltd
VEON
77.19
+0.78
+1.02%
VEON Ltd
US · VEON
#2095 by market cap
Listed 1970
77.19
+0.78
+1.02%
Live - 5344 symbols - heartbeat 455s ago
· 2026-10-07 19:54
After-hours
77.19
0.00%
- Market cap
- 5.32B
- P/E (TTM)i
- 77.19
- P/Bi
- 3.53
- EPSi
- 7.50
- Div yieldi
- 0.00%
- 52W posi
- 95%
Reader sentiment
Are you bullish or bearish on VEON?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 0.78, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +9.87% YoY
Margins
- Gross margin
- 88.04%
- Operating margin
- 24.37%
- Net margin
- 12.09%
Key ratios & quality
- Altman Z-Scorei
- 0.78
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 9.09B | 8.09B | 3.48B | 3.85B | 3.76B | 3.70B | 4.00B | 4.40B |
| Gross profit | 6.97B | 6.25B | 3.03B | 3.37B | 3.28B | 3.26B | 3.49B | 3.87B |
| Selling & admin expenses | 3.42B | 2.53B | 1.36B | 1.46B | 1.48B | 1.56B | 1.71B | 1.80B |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 1.50B | 2.07B | 917.00M | 1.06B | 997.00M | 891.00M | 983.00M | 1.07B |
| Pretax profit | -248.00M | 1.04B | 373.00M | 464.00M | 802.00M | 559.00M | 704.00M | 785.00M |
| Tax | 369.00M | 462.00M | 279.00M | 344.00M | 69.00M | 179.00M | 217.00M | 194.00M |
| Net profit | 362.00M | 683.00M | -316.00M | 801.00M | -9.00M | -2.45B | 487.00M | 591.00M |
| Basic EPS | 8 | 9 | -5 | 10 | -2 | -36 | 6 | 8 |
| Diluted EPS | 8.25 | 9.00 | -5.00 | 9.50 | -2.25 | -36.00 | 5.75 | 7.50 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 1.03B | 1.09B | 1.12B | 1.17B | 1.20B | 1.27B |
| Gross profit | 897.00M | 983.00M | 982.00M | 1.01B | 1.05B | 1.10B |
| Selling & admin expenses | 458.00M | 464.00M | 633.00M | 244.00M | 533.00M | 550.00M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 241.00M | 324.00M | 157.00M | 349.00M | 308.00M | 327.00M |
| Pretax profit | 130.00M | 682.00M | -83.00M | 56.00M | 183.00M | 200.00M |
| Tax | 12.00M | 74.00M | 44.00M | 64.00M | 60.00M | 60.00M |
| Net profit | 118.00M | 608.00M | -127.00M | -8.00M | 123.00M | 140.00M |
| Basic EPS | 2 | 9 | -2 | -1 | 2 | 2 |
| Diluted EPS | 1.50 | 8.50 | -1.91 | -0.55 | 1.50 | 1.75 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 3.11B | 2.50B | 2.85B | 5.42B | 9.77B | 3.16B | 2.89B | 3.11B |
| Cash & ST investments | 1.90B | 1.33B | 1.76B | 2.34B | 3.23B | 2.34B | 2.05B | 2.22B |
| Inventory | 141.00M | 169.00M | 111.00M | 111.00M | 18.00M | 23.00M | 15.00M | 32.00M |
| Total assets | 14.10B | 16.06B | 14.55B | 15.92B | 15.08B | 8.22B | 8.04B | 9.22B |
| Total current liabilities | 4.41B | 5.77B | 4.41B | 4.77B | 8.88B | 3.58B | 3.65B | 3.44B |
| Short-term debt | 1.29B | 2.59B | 1.26B | 1.24B | 2.84B | 1.69B | 1.67B | 1.10B |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 11,323,000,000.00 | 13,839,000,000.00 | 13,538,000,000.00 | 14,416,000,000.00 | 14,316,000,000.00 | 7,147,000,000.00 | 6,779,000,000.00 | 7,581,000,000.00 |
| Total equity | 2.78B | 2.22B | 1.01B | 1.51B | 767.00M | 1.07B | 1.26B | 1.63B |
| Retained earnings | -1.41B | -1.33B | -1.92B | -1.25B | -1.41B | -3.94B | -3.53B | -3.00B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 3.04B | 2.65B | 2.88B | 3.11B | 3.12B | 3.71B |
| Cash & ST investments | 2.13B | 1.28B | 1.66B | 2.22B | 2.18B | 2.69B |
| Inventory | 16.00M | -- | -- | 32.00M | 29.00M | 32.00M |
| Total assets | 8.25B | 8.46B | 8.81B | 9.22B | 9.60B | 10.27B |
| Total current liabilities | 3.76B | 3.03B | 3.04B | 3.44B | 3.63B | 3.83B |
| Short-term debt | 1.70B | 1.06B | 1.11B | 1.10B | 1.42B | 1.44B |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 6,858,000,000.00 | 6,967,000,000.00 | 7,167,000,000.00 | 7,581,000,000.00 | 7,739,000,000.00 | 8,348,000,000.00 |
| Total equity | 1.39B | 1.50B | 1.65B | 1.63B | 1.86B | 1.92B |
| Retained earnings | -3.43B | -- | -- | -3.00B | -2.90B | -2.78B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 2.52B | 2.95B | 2.44B | 2.64B | 2.56B | 2.11B | 1.15B | 1.35B |
| Depreciation & amortization | 2.69B | 1.95B | 792.00M | 799.00M | 671.00M | 729.00M | 731.00M | 811.00M |
| Free cash flow | 567.00M | 1.37B | 1.76B | 1.78B | 1.55B | 1.35B | 243.00M | 404.00M |
| Dividends paid | -508.00M | -520.00M | -259.00M | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | 0 | 0 | -8.00M | 27.00M |
| Ending cash balance | 1.79B | 1.24B | 1.66B | 2.24B | 3.11B | 1.90B | 1.69B | 1.73B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 433.00M | 137.00M | 323.00M | 462.00M | 396.00M | 464.00M |
| Depreciation & amortization | 198.00M | -- | -- | -- | 209.00M | 225.00M |
| Free cash flow | 224.00M | 137.00M | 323.00M | -487.00M | 132.00M | 251.00M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -24.00M | -- | -- | -- | -28.00M | -34.00M |
| Ending cash balance | 1.77B | 1.28B | 1.66B | 1.73B | 1.75B | 2.19B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 14.51 | 25.37 | -50.25 | 179.97 | -28.05 | -354.31 | 42.41 | 43.62 |
| ROA %i | 3.46 | 4.12 | -2.28 | 4.42 | -1.05 | -21.70 | 5.11 | 6.17 |
| ROIC %i | 8.87 | 9.91 | 1.10 | 10.78 | 3.42 | -29.91 | 12.26 | 14.59 |
| 5-year avg ROE %i | 5.78 | 12.61 | 5.55 | 31.96 | 28.32 | -45.45 | -42.05 | -23.27 |
| EBIT margin %i | 6.25 | 23.39 | 8.88 | 20.52 | 36.88 | 29.48 | 29.95 | 30.01 |
| FCF / sales %i | 6.24 | 14.28 | 8.33 | 10.82 | 41.20 | 36.37 | 6.07 | 9.18 |
| Current ratioi | 0.70 | 0.43 | 0.65 | 1.13 | 1.10 | 0.88 | 0.79 | 0.91 |
| Quick ratioi | 0.62 | 0.37 | 0.58 | 0.68 | 0.43 | 0.83 | 0.71 | 0.85 |
| Debt / assetsi | 55.71 | 64.41 | 69.32 | 66.87 | 54.23 | 62.74 | 58.41 | 55.83 |
| LT debt / equityi | 178.94 | 632.87 | 5,418.40 | 1,604.78 | 937.79 | 403.73 | 275.52 | 301.72 |
| Interest coveragei | 0.70 | 2.32 | 1.04 | 2.32 | 2.38 | 2.05 | 2.42 | 2.47 |
| Revenue CAGR (3Y) %i | -1.84 | -3.08 | -28.37 | -24.89 | -22.57 | 2.03 | 1.32 | 5.42 |
| Net income CAGR (3Y) %i | -- | -35.63 | -- | 5.01 | -- | -- | -14.93 | -- |
| FCF CAGR (3Y) %i | -- | 82.70 | 59.01 | 46.42 | 4.23 | -8.59 | -48.51 | -36.08 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 37.86 | 87.51 | 43.93 | 43.62 | 39.78 | 4.17 |
| ROA %i | 5.54 | 12.34 | 7.31 | 6.17 | 5.96 | 0.63 |
| ROIC %i | 13.15 | 24.16 | 15.87 | 14.59 | 13.93 | 6.36 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 29.28 | 42.19 | 32.92 | 30.01 | 30.70 | 20.22 |
| FCF / sales %i | 10.20 | 9.04 | 8.21 | 9.18 | 6.82 | 13.49 |
| Current ratioi | 0.81 | 0.87 | 0.95 | 0.91 | 0.86 | 0.97 |
| Quick ratioi | 0.72 | 0.59 | 0.73 | 0.85 | 0.79 | 0.90 |
| Debt / assetsi | 57.03 | 58.05 | 58.35 | 55.83 | 56.48 | 57.00 |
| LT debt / equityi | 249.13 | 292.93 | 275.03 | 301.72 | 272.75 | 291.94 |
| Interest coveragei | 2.48 | 3.54 | 2.71 | 2.47 | 2.48 | 1.59 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Single segment100.00%
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.